Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;10(2):336-46.
doi: 10.1158/1535-7163.MCT-10-0750.

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to _targeted therapy

Noriaki Sunaga  1 , David S Shames, Luc Girard, Michael Peyton, Jill E Larsen, Hisao Imai, Junichi Soh, Mitsuo Sato, Noriko Yanagitani, Kyoichi Kaira, Yang Xie, Adi F Gazdar, Masatomo Mori, John D Minna
Affiliations

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to _targeted therapy

Noriaki Sunaga et al. Mol Cancer Ther. 2011 Feb.

Abstract

Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non-small cell lung cancer (NSCLC), and is an important _target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-mutant NSCLC cells, but not in NSCLC cells that have wild-type KRAS (but mutant NRAS). Surprisingly, we did not see large-scale induction of cell death and the growth inhibitory effect was not complete. To further understand the ability of NSCLCs to grow despite selective removal of mutant KRAS expression, we conducted microarray expression profiling of NSCLC cell lines with or without mutant KRAS knockdown and isogenic human bronchial epithelial cell lines with and without oncogenic KRAS. We found that although the mitogen-activated protein kinase pathway is significantly downregulated after mutant KRAS knockdown, these NSCLCs showed increased levels of phospho-STAT3 and phospho-epidermal growth factor receptor, and variable changes in phospho-Akt. In addition, mutant KRAS knockdown sensitized the NSCLCs to p38 and EGFR inhibitors. Our findings suggest that _targeting oncogenic KRAS by itself will not be sufficient treatment, but may offer possibilities of combining anti-KRAS strategies with other _targeted drugs.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

All authors have no financial or personal relationships with other people or organizations that could inappropriately influence our work.

Figures

Fig. 1
Fig. 1
(A) Immunoblot of KRAS protein expression in H23, H1792, H358, H441, H1299 NSCLC cell lines. Thirty μg of whole cell lysate was loaded per lane and Western Blot was performed. (B) Positive correlation between KRAS copy number and the protein expression levels in NSCLC cell lines (Pearson r = 0.9636, P = 0.0083). The protein expression levels were determined by densitometry. (C) Stable knockdown of mutant KRAS protein by retroviral-mediated shRNA in NSCLC cell lines. P: parental cells, Mock: pRS control vector-infected cells, KRAS-C: pRS-KRAS-C12-infected cells, KRAS-V: pRS-KRAS-V12-infected cells. (D) Specific reduction of mutant KRAS transcripts by retroviral shRNA vectors (pRS-KRAS-C12 or pRS-KRAS-V12) but not by the pRS control vector in the NSCLC cells. BstNI digestion cuts the wild-type KRAS allele (e.g., H1299 cells) to produce a 156-bp DNA fragment whereas the mutant KRAS allele remains uncut to produce a 186-bp DNA fragment (e.g., the H2122 cell line that has a homozygous KRAS G12C mutation was used as a control).
Fig. 1
Fig. 1
(A) Immunoblot of KRAS protein expression in H23, H1792, H358, H441, H1299 NSCLC cell lines. Thirty μg of whole cell lysate was loaded per lane and Western Blot was performed. (B) Positive correlation between KRAS copy number and the protein expression levels in NSCLC cell lines (Pearson r = 0.9636, P = 0.0083). The protein expression levels were determined by densitometry. (C) Stable knockdown of mutant KRAS protein by retroviral-mediated shRNA in NSCLC cell lines. P: parental cells, Mock: pRS control vector-infected cells, KRAS-C: pRS-KRAS-C12-infected cells, KRAS-V: pRS-KRAS-V12-infected cells. (D) Specific reduction of mutant KRAS transcripts by retroviral shRNA vectors (pRS-KRAS-C12 or pRS-KRAS-V12) but not by the pRS control vector in the NSCLC cells. BstNI digestion cuts the wild-type KRAS allele (e.g., H1299 cells) to produce a 156-bp DNA fragment whereas the mutant KRAS allele remains uncut to produce a 186-bp DNA fragment (e.g., the H2122 cell line that has a homozygous KRAS G12C mutation was used as a control).
Fig. 2
Fig. 2
(A) The effects of KRAS knockdown on the phosphorylation of MEK, ERK, Akt, STAT3 and EGFR in the KRAS mutation-positive NSCLC cell lines. Thirty μg of whole cell lysate was loaded per lane for western blot analysis. Mock: pRS vector-infected cells, KRAS-C: pRS-KRAS-C12-infected cells, KRAS-V: pRS-KRAS-V12-infected cells. (B) The effect of KRAS knockdown on the phosphoprotein levels. The data were obtained from three independent experiments.
Fig. 2
Fig. 2
(A) The effects of KRAS knockdown on the phosphorylation of MEK, ERK, Akt, STAT3 and EGFR in the KRAS mutation-positive NSCLC cell lines. Thirty μg of whole cell lysate was loaded per lane for western blot analysis. Mock: pRS vector-infected cells, KRAS-C: pRS-KRAS-C12-infected cells, KRAS-V: pRS-KRAS-V12-infected cells. (B) The effect of KRAS knockdown on the phosphoprotein levels. The data were obtained from three independent experiments.
Fig. 3
Fig. 3
The effects of (A) p38 V, (B) gefitinib, and (C) cetuximab on colony formation in H23, H1792, H358 and H441 cells with KRAS knockdown (red line) or without KRAS knockdown (blue line) at various concentrations. Number of colonies in untreated cells was set at 100%. The data were obtained from six independent experiments. *, P<0.05; **, P <0.01; ***, P <0.001.
Fig. 3
Fig. 3
The effects of (A) p38 V, (B) gefitinib, and (C) cetuximab on colony formation in H23, H1792, H358 and H441 cells with KRAS knockdown (red line) or without KRAS knockdown (blue line) at various concentrations. Number of colonies in untreated cells was set at 100%. The data were obtained from six independent experiments. *, P<0.05; **, P <0.01; ***, P <0.001.
Fig. 3
Fig. 3
The effects of (A) p38 V, (B) gefitinib, and (C) cetuximab on colony formation in H23, H1792, H358 and H441 cells with KRAS knockdown (red line) or without KRAS knockdown (blue line) at various concentrations. Number of colonies in untreated cells was set at 100%. The data were obtained from six independent experiments. *, P<0.05; **, P <0.01; ***, P <0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med. 2003;54:73–87. - PubMed
    1. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2007 Apr;2(4):327–43. - PubMed
    1. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly _targeted therapies for lung cancer. J Clin Invest. 2007 Oct;117(10):2740–50. - PMC - PubMed
    1. Downward J. _targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003 Jan;3(1):11–22. - PubMed
    1. Suda K, Tomizawa K, Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts withEGFR mutation. Cancer Metastasis Rev. 2010 Mar;29(1):49–60. - PubMed

Publication types

MeSH terms

  NODES
Project 1
twitter 2